"Atopic Dermatitis (AD) Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Atopic Dermatitis (AD) market.
A detailed picture of the Atopic Dermatitis (AD) pipeline landscape is provided, which includes the disease overview and Atopic Dermatitis (AD) treatment guidelines. The assessment part of the report embraces in-depth Atopic Dermatitis (AD) commercial assessment and clinical assessment of the Atopic Dermatitis (AD) pipeline products from the pre-clinical developmental phase to the marketed phase.
Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. Treatments for AD need to rapidly control symptoms of the disease, improve quality of life and prevent exacerbations. The recognition of the genes responsible for defective barrier function is key to immune modulation and the development of newer classes of therapies, including Janus kinase signaling pathway inhibitors, additional PDE4 inhibitors, and agonists of the aryl hydrocarbon receptor.
Atopic dermatitis pipeline products
Expected launch of PF-04965842 (Pfizer), ZPL389 (Novartis Pharmaceuticals), DS-2741a (Daiichi Sankyo), Upadacitinib (AbbVie), PUR0110 (PurGenesis Technologies), Lebrikizumab (Dermira)and other shall fuel the growth of the market during the forecast period, i.e., 2020–2030.
Extensive research and development activities of pharmaceutical companies for developing the therapies for AD will significantly impact the market. Drugs in the clinical trials are expected to propel the growth of the AD drugs market in the upcoming years.
Key players such as Pfizer, Novartis Pharmaceuticals, Daiichi Sankyo, AbbVie, PurGenesis Technologies, Dermira and other are involved in developing therapies for Atopic Dermatitis.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis (AD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Atopic Dermatitis (AD).
- In the coming years, the Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Atopic Dermatitis (AD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Atopic Dermatitis (AD) treatment market. Several potential therapies for Atopic Dermatitis (AD) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Atopic Dermatitis (AD) market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Atopic Dermatitis (AD)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Table of contents
1. Report Introduction
2. Atopic Dermatitis (AD)
3. Atopic Dermatitis (AD) Current Treatment Patterns
4. Atopic Dermatitis (AD) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Atopic Dermatitis (AD) Late Stage Products (Phase-III)
7. Atopic Dermatitis (AD) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atopic Dermatitis (AD) Discontinued Products
13. Atopic Dermatitis (AD) Product Profiles
14. Atopic Dermatitis (AD) Key Companies
15. Atopic Dermatitis (AD) Key Products
16. Dormant and Discontinued Products
17. Atopic Dermatitis (AD) Unmet Needs
18. Atopic Dermatitis (AD) Future Perspectives
19. Atopic Dermatitis (AD) Analyst Review
20. Appendix
21. Report Methodology
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/
